ArticleTranslational pediatrics2025
Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening emergency in neonatal intensive care. Traditional treatments such as cylinder-based nitric oxide (NO) delivery systems rely on large, fixed equipment, creating limitations during neonatal transport or treatment in primary hospitals, which may delay critical intervention. Moreover, neonates exhibit high physiological vulnerability, imposing stricter requirements on the safety and portability of therapeutic devices. Novlead Biotech in China has developed a novel portable inhaled nitric oxide (iNO) generator (PG-iNO), which shows promise in overcoming these obstacles. This study aims to assess the safety of PG-iNO for the treatment of PPHN using a descriptive study. Methods: The data of seven newborns diagnosed with PPHN and having received PG-iNO from December 1, 2023 to January 31, 2024 were retrieved from medical records. Demographic and clinical features, vital signs, arterial blood gas, ventilation indicators, measurement of preductal and postductal oxygen saturation, mortality, and comorbidities were evaluated before and after the administration of PG-iNO therapy. Results: All enrolled patients survived and reported few side effects during the administration of PG-iNO. A significant improvement in oxygenation index (OI), fraction of inspired oxygen (FiO Conclusions: The PG-iNO demonstrates safety in the treatment of neonatal PPHN. However, large-scale, prospective trials are needed to further validate its long-term safety and efficacy, particularly in preterm infants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.